Introduction
The urokinase-type plasminogen activator is a serine protease that converts the inert zymogen plasminogen into plasmin a protease with broad substrate speci®city (Nielsen et al., 1982; Robbins et al., 1967) . Urokinase can bind speci®cally and with high anity (K D 90.5 nM) to a 45 ± 60 kDa heavily glycosylated cell surface receptor (u-PAR) (Stoppelli et al., 1986; Vassalli et al., 1985) . The receptor is comprised of three similar repeats approximately 90 residues each Riittinen et al., 1996) . The aminoterminal domain binds the plasminogen activator with the carboxyterminus domain serving to anchor the binding protein to the cell surface via a glycosylphosphatidylinositol chain Riittinen et al., 1996) . The u-PAR gene is 7 exons long and is located on chromosome 19q13 (Vagnarelli et al., 1992; Casey et al., 1994) . Transcription of the u-PAR gene gives rise to a 1.4 kb mRNA or an alternatively spliced variant lacking the membrane attachment peptide sequence (Roldan et al., 1990; Pyke et al., 1993) . The amounts of u-PAR are controlled mainly at the transcriptional level through 398 base pairs of upstream sequence but altered message stability and receptor recycling may represent other means of controlling the amount of this gene product at the cell surface (Lengyel et al., 1996; Shetty et al., 1997; Lund et al., 1995; Nykjaer et al., 1997) .
The u-PAR has been implicated in a number of physiological and pathological processes involving tissue remodeling. For example, subsequent to injury, regenerating epithelial outgrowths express u-PAR mRNA in keratinocytes at the leading edge (Romer et al., 1994) . Similarly, wounded endothelial cells in monolayer rapidly up-regulate their u-PAR expression (Pepper et al., 1993) . In cancer, it appears that the u-PAR plays a prominent role in tumor cell invasion and metastasis and this may very well represent an extension of its physiological role as described previously. Earlier studies have shown that the overexpression of a human u-PAR cDNA increased the ability of human osteosarcoma cells to invade into an extracellular matrix-coated porous ®lter (Kariko et al., 1993) . Conversely, down-regulating u-PAR levels using either antisense expression constructs, oligonucleotides, or synthetic compounds reduced the ability of Hep3 squamous cell carcinoma, breast cancer cells and transformed ®broblasts to demonstrate an invasive phenotype in vitro and in vivo (Kook et al., 1994; Xing et al., 1997; Quattrone et al., 1995) . Similarly, Min et al. (1996) found that a u-PAR antagonist inhibited neovascularization and B16 melanoma growth while Wilhelm et al. (1994) demonstrated that soluble u-PAR used as a scavenger inhibited the in vitro invasion of ovarian cancer cells. In clinical studies, Bianchi et al. (1994) detected u-PAR in the tumor cells and macrophages of breast cancer patients but not in normal or benign breast tissue while the binding site appears frequently in advanced metastatic melanoma (de Vries et al., 1994) . Further, Allgayer et al., 1997; Heiss et al., 1995 found that u-PAR-positive tumor cells in the bone marrow of gastric cancer patients was potentially an indicator of a metastatically-relevant population in a pool of minimal residual tumor cells. Finally, a high u-PAR protein level in colon cancer patients predicts a poor 5 year outcome (Ganesh et al., 1994) .
The u-PAR is a multi-functional molecule and it is probable that one or more of these attributes contributes to tissue remodeling in both physiological and pathological processes. First, urokinase bound to the u-PAR activates plasminogen at a much faster rate than¯uid-phase plasminogen activator (Ellis et al., 1991; Higazi et al., 1995) . A second function of the binding site is to clear urokinase-inhibitor complexes from the extracellular space Conese et al., 1994) and this occurs through a mechanism involving the a2 macroglobulin receptor (Conese et al., 1994) . Third, it is now evident that the u-PAR interacts with the extracellular domain of integrins to connect to the cytoskeleton thereby mediating cell adhesion and migration (Wei et al., 1996; Yebra et al., 1996; Bohuslav et al., 1995) . Fourth, the u-PAR is chemotactic for human monocytes and mast cells (Resnati et al., 1996; Sillaber et al., 1997) and, in some instances (Resnati et al., 1996) , this may require the cleavage of the binding site between domains 1 and 2.
Previous studies have shown that u-PAR transcription is strongly induced by the phorbol ester PMA (Picone et al., 1989; Lund et al., 1991) and we reported previously that this was mediated in part through an AP-1 motif located 184 base pairs upstream of the u-PAR transcriptional start site (Lengyel et al., 1996) . How small molecules, such as PMA, and c-Ha-ras that act at, or close to, the cell surface transduce their signal to the cell nucleus has been the subject of intense scrutiny. The latter is of particular interest since previous studies have implicated the overexpression of c-Ha-Ras/K-ras and/or its mutation-activation in several malignancies including ovarian and colon cancer (Bos, 1989; Chien et al., 1993; van Dam et al., 1994; Palejwala et al., 1996; Scambia et al., 1997) . Recent studies have reported on parallel signaling cascades which connect the cell surface to the nucleus. In the classical pathway (hereafter referred to as c-Raf-1-ERK), Ras stimulation leads to the sequential activation of c-Raf-1, MEK1 and the extracellular signal-regulated kinase(s) (ERK) subset of mitogenactivated protein kinases (MAPK) (Zheng and Guan. 1994; Jelinek et al., 1994; Minden et al., 1994b; Huang et al., 1993; Crews et al., 1992 ) the latter modulating the activity and/or synthesis of a number of transcription factors including c-Fos and ATF-2 (Gille et al., 1992; Rao and Reddy 1993; AbdelHa®z et al., 1996; McCarthy et al., 1997; Janknecht, 1996) . More recently, an alternate pathway utilized mainly by stress and death inducers such as ultraviolet light, gamma radiation and osmotic shock has been reported (Chen et al., 1996; Minden et al., 1994a; Hibi et al., 1993; Derijard et al., 1994) . This Ras-activated signaling module consists of the sequential activation of Rac1, MEKK1, c-Jun amino-terminal kinase kinase (JNKK) and the cJun amino terminal kinase (JNK) subset of MAPK (Olson et al., 1995; Minden et al., 1996; Lin et al., 1995; Derijard et al., 1995) . JNKs regulate the transactivating activity of c-Jun via phosphorylation of its aminoterminus (Hibi et al., 1993; Minden et al., 1994b; Adler et al., 1994) . Additionally, these MAPKs phosphorylate other transcription factors including Sap-1a, p62 TCF and ATF-2 (Whitmarsh et al., 1995; Cavigelli et al., 1995; Janknecht and Hunter, 1997; Davis, 1995) . However, a prevailing view is that the ability of phorbol ester to alter inducible gene expression is mediated through the classical signaling module (cRaf-1-ERK) and several observations by other investigators have supported this view. Thus, PMA induces ERK activity in a number of systems (Jones et al., 1994; Masuelli and Cutler, 1996; Whalen et al., 1997; de Vries-Smits et al., 1992; Bogoyevitch et al., 1995; Cano et al., 1995) and the co-expression of kinase-defective ERK1/ERK2 expression constructs inhibits the PMA-dependent stimulation of AP-1-regulated gene expression (Frost et al., 1994) . Further, Protein Kinase C, the receptor for PMA, binds to and activates c-Raf-1 leading to ERK activation (Cai et al., 1997; Marquardt et al., 1994; Sozeri et al., 1992; Berra et al., 1995; Sauma and Friedman, 1996) . On the other hand, several studies have demonstrated that JNK activity in the parallel signaling cascade is either not stimulated or only weakly activated by this phorbol ester Minden et al., 1994b; Hibi et al., 1993; Ludwig et al., 1996; Bogoyevitch et al., 1995; Cano et al., 1995) . While the cited studies would predict that the eect of PMA on u-PAR expression is mediated through the c-Raf-1-ERK pathway, it is now becoming apparent that these signaling modules are by no means linear and, in fact, there is increasing evidence for cross-talk between the various cascades (Bogoyevitch et al., 1995) . With this in mind, we undertook a study with two objectives, namely to determine the requirement of JNK1 for (a) the stimulation of u-PAR expression by PMA and (b) u-PAR promoter stimulation by cHa-ras, which has been shown to be both overexpressed and mutation-activated in several maligIncreased u-PAR expression by PMA and c-Ha-ras is JNK1 dependent R Gum et al Figure 1 The PMA-dependent increase in JNK activity precedes the rise in u-PAR protein levels. (a) OVCAR-3 cells were treated with 100 nM PMA for varying periods of time after which the cells were lysed and equal protein amounts in the cell extracts immunoprecipitated with an anti-JNK antibody. Subsequently, the immunoprecipitate was washed and incubated with 2 mg of a cJun-GST fusion protein in the presence of [g 32 P]ATP. Radioactive products were resolved by SDS ± PAGE and visualized by autoradiography. (b) Cells treated as for a were lysed at the indicated times and equal protein amounts in the extracts immunoprecipitated with an anti ERK1/ERK2 antibody. The immunoprecipitate was resolved in an SDS-polyacrylamide gel containing myelin basic protein. The gel was subsequently incubated with [g 32 P]ATP and autoradiographed. (c) Cells treated as described in a, were harvested and lysed and equivalent protein amounts immunoprecipitated with a polyclonal anti-u-PAR antibody. Immunoprecipitated material was resolved by SDS ± PAGE and proteins transferred to a nitrocellulose ®lter. The ®lter was probed with a monoclonal antibody speci®c for u-PAR and reactive bands visualized by ECL. In the +ve and 7ve controls, cell extract from a cell line (RKO), that overexpresses u-PAR (Lengyel et al., 1996) or buer only, respectively, were immunoprecipitated with the polyclonal anti-u-PAR antibody. (d, e) OVCAR-3 cells were treated with varying concentrations of PMA. The cells were lysed after 30 min (d) and 4 h (e) and the extracts asayed for JNK activity (as described in a) and for u-PAR (as described in c) respectively. In the lane`No Ab' the immunoprecipitating antibody was not added. The experiment was repeated twice Increased u-PAR expression by PMA and c-Ha-ras is JNK1 dependentnancies including ovarian cancer (Bos, 1989; Chien et al., 1993; van Dam et al., 1994; Palejwala et al., 1996; Scambia et al., 1997) .
Results

PMA coordinately regulates u-PAR protein levels and JNK activity
If PMA regulates u-PAR expression by way of altered JNK activity, then the change in activity of this MAPK should precede altered u-PAR protein levels. To test this, the following experiment was carried out. OVCAR-3 cells, which are de®cient in u-PAR and JNK activity, were treated with 100 nM PMA for varying periods of time, and cell extracts assayed for JNK and ERK activity and u-PAR protein. Treatment of the cells with PMA caused a rapid increase in JNK activity evident within 5 min (Figure 1a) . After 30 min with phorbol ester, JNK activity was increased about 15-fold. JNK activity thereafter declined returning to pretreatment levels after 16 h. The stimulation of JNK activity was quantitatively similar to the induction of ERK1 activity (maximal activation of 13-fold observed after 30 min) (Figure 1b) . It is worth noting that the increase in JNK activity is unlikely to be a consequence of an activated ERK1-dependent signaling cascade since it coincided with, rather than lagged, the rise in ERK1 activity. It is also unlikely that JNK activation by PMA in OVCAR-3 cells is secondary to increased growth as the phorbol ester did not stimulate the growth rate of these cells. The increase in JNK activity preceded the induction of u-PAR protein levels which was ®rst apparent after 2 h of phorbol ester treatment ( Figure 1c ). Maximal u-PAR protein induction was evident after 16 of treatment compared with 30 min for JNK stimulation.
In dose-response studies, the stimulation of JNK activity also correlated with u-PAR protein amount. Thus, while 1 nM of the phorbol ester was sub-optimal for elevating JNK activity ( Figure 1d ) and u-PAR protein (Figure 1e ), a concentration of 10 nM PMA resulted in maximal induction of these two measurements.
Stimulation of u-PAR promoter activity by PMA requires an intact AP-1 motif at 7184
We previously demonstrated the requirement of an AP-1 motif located 184 base pairs upstream of the transcriptional start site for the stimulation of u-PAR expression by phorbol ester in the GEO colon cancer cell line (Lengyel et al., 1996) . To con®rm that a similar requirement exists for OVCAR-3 cells, these cells were transiently transfected with a CAT reporter driven by either the wild type promoter or the promoter in which the AP-1 motif at 7184 was mutated and subsequently treated with, or without, PMA. In the absence of the phorbol ester, the activity of both the wild type and the AP-1-mutated u-PAR promoter was very low (about 5% chloramphenicol acetylated). However, treatment with 50 nM PMA caused a strong stimulation (16-fold compared with Figure 2 c-Jun is bound to the u-PAR AP-1 motif in nuclear extracts prepared from PMA-treated OVCAR-3 cells. OVCAR-3 cells were treated with either 100 nM PMA, for 30 min or 2 h, or with DMSO (0.05%) for 2 h and nuclear extracts prepared. Nuclear extract (6 mg protein) was incubated with an oligonucleotide spanning the AP-1 motif (at 7184) of the u-PAR promoter either in the presence, or absence, of a 100-fold excess of the unlabeled sequence (Competitor). After 10 min, antibodies (2 mg) against the indicated transcription factor were added and the reaction mixture subsequently subjected to gel electrophoresis. The gel was exposed to ®lm for 2.5 or 7.5 h. The data are typical of duplicate experiments Increased u-PAR expression by PMA and c-Ha-ras is JNK1 dependent R Gum et al no treatment) of the wild type u-PAR promoter. In contrast, the stimulation of the AP-1-mutated u-PAR promoter was reduced over 60% compared with that evident with the wild type promoter. Thus, stimulation of u-PAR expression by PMA in OVCAR-3 cells requires an intact AP-1 motif at 7184.
c-Jun, the target of JNK, is bound to the u-PAR AP-1 motif at 7184 in PMA-treated OVCAR-3 cells JNK modulates AP-1-dependent gene expression by increasing the transactivating potential of c-Jun via phosphorylation of the amino-terminus region of this transcription factor (Hibi et al., 1993; Minden et al., 1994b) . If PMA stimulates u-PAR expression by way of JNK activation we would predict that the AP-1 motif at 7184 would be bound with this transcription factor. To investigate this possibility, OVCAR-3 cells were treated with PMA, nuclear extracts generated and used in mobility shift assays ( Figure  2 ). Nuclear extract from control OVCAR-3 cells (DMSO) caused a shift in mobility of the AP-1-spanning u-PAR promoter oligonucleotide. The slower moving complexes were speci®c since a 100-fold excess of unlabeled probe abolished these bands.
The addition of an anti-c-Jun antibody to the mixture of oligonucleotide and nuclear extract prepared from PMA-treated cells (cultured with the phorbol ester for either 30 min or 2 h) revealed a supershifted complex (arrow) with a concomitant decrease in the intensity of one of the shifted bands (*). Thus, using nuclear extracts from PMA-treated cells, c-Jun, which is a target of JNK, is bound to the u-PAR promoter AP-1 motif. We also observed that using nuclear extracts prepred from PMA-treated cells, c-Fos, a target of both the ERK and JNK pathways (Cavigelli et al., 1995; Janknecht and Hunter, 1997; Gille et al., 1992) , was bound to the AP-1-spanning oligonucleotide.
PMA stimulates transcription from a synthetic promoter regulated by the transactivation domain of c-Jun fused to the DNA-binding domain of Gal4
To obtain further evidence for JNK involvement in the stimulation of u-PAR expression by PMA, we made use of the Pathdetect system (Stratagene, La Jolla, California) which detects the trans-activating activity of c-Jun. OVCAR-3 cells were co-transfected with a luciferase reporter regulated by ®ve tandem repeated GAL4 binding sites and an expression vector encoding a chimeric protein comprised of the transactivation domain of c-Jun (aminoterminus) fused to the GAL4 DNA-binding domain. The transfected cells were then treated with, or without, PMA and assayed for luciferase activity. Luciferase activity in OVCAR-3 cells transfected with the reporter construct and the DNA-binding domain only (pFC dbd) was low and not induced by PMA treatment (pFC dbd + PMA) (Figure 3 ). In contrast, PMA stimulated luciferase activity over fourfold in OVCAR-3 cells made to express the c-Jun-GAL4 DNA-binding domain chimeric protein and the reporter construct (compare pFA c-Jun + PMA with pFA c-Jun). The background luciferase activity evident in OVCAR-3 cells not treated with PMA (pFA c-Jun) probably re¯ects the basal JNK activity as seen in immunocomplex kinase assays ( Figure 1a) . Interestingly, the increased transactivation brought about by PMA was quantitatively similar to that observed for the positive control where a known upstream activator of JNK (MEKK) was used (pFA c-Jun +pFC MEKK). These data suggest that the transactivating activity of c-Jun is augmented by PMA to an extent similar to that observed when the JNK pathway is activated by a physiological stimulus (MEKK).
The expression of dominant negative JNK1 or MEKK1 constructs inhibits the PMA-dependent stimulation of u-PAR promoter activity
We then determined the eect of expressing either kinase-defective JNK1 or MEKK1 expression constructs (see Figure 4 ) on the stimulation of u-PAR promoter activity by PMA. OVCAR-3 cells were cotransfected with a CAT reporter regulated by the wild type u-PAR promoter and an expression construct encoding a kinase-defective JNK1 (Derijard et al., 1994) . Transfected cells were then treated with, or without PMA, and subsequently assayed for CAT activity. The activity of a promoter-less CAT reporter (pSV 0 CAT) was below the detection limits of the CAT assay and was not increased after treatment of the cells with the phorbol ester ( Figure 5a ). The activity of the u-PAR promoter-regulated CAT Figure 3 PMA stimulates the trans-activating activity of c-Jun. OVCAR-3 cells were co-transfected with a GAL4-regulated luciferase reporter (1 mg) construct and 5 mg of an expression vector encoding either the DNA-binding domain of GAL4 (pFC dbd) or the transactivation domain of c-Jun fused to the GAL4 DNA-binding domain (pFA c-Jun). After 6 h, the cells were washed and replenished with fresh culture medium supplemented with, or without, 100 nM PMA or a corresponding amount (0.05%) of the carrier (DMSO). After an additional 48 h, the cells were harvested, lysed and the extract (10 mg protein) assayed for luciferase activity. As a positive control, OVCAR-3 cells were transiently co-transfected with a GAL4-regulated luciferase reporter, an expression vector bearing the coding sequence of MEKK (pFC MEKK) and a plasmid bearing either the DNAbinding domain of GAL4 (pFC dbd) or the transactivation domain of c-Jun fused to the GAL4 DNA-binding domain (pFA c-Jun). The data are typical of duplicate experiments reporter was also undetectable in OVCAR-3 cells not exposed to the phorbol ester. However, treatment with PMA caused a dramatic stimulation of transcription from the u-PAR promoter-regulated CAT reporter. The co-expression of an equimolar amount of the dominant negative JNK1 expression construct ( Figure  5a ) reduced CAT activity by 35% when compared with the empty expression construct (SRa Vector).
Increasing the amount of the DNA encoding the kinase-inactive JNK1 to a fourfold molar excess further reduced u-PAR promoter activity by 80% (compared with a 46 molar excess of the empty vector-SRa Vector).
To corroborate the data generated with the kinase-de®cient JNK1 expression constructs, parallel experiments were conducted employing a kinaseinactive MEKK1 expression construct. MEKK1 is a known upstream activator of JNK . Expression of the dominant negative MEKK1 caused a marked repression of the PMA-dependent stimulation of u-PAR promoter activity (Figure 5b) . A 0.16 molar amount (relative to the reporter construct) of the MEKK1 mutant expression construct caused an approximate 75% reduction in u-PAR promoter activity when compared with that achieved with the empty expression construct (SRa Vector). Increasing the amount of DNA to an equimolar level resulted in approximately a 90% inhibition of u-PAR promoter stimulation by PMA. The greater potency of the dominant negative MEKK, compared with the mutated JNK1 expression construct, in countering the stimulation of u-PAR promoter activity by PMA deserves comment. This could very well re¯ect the suppression of an alternative parallel pathway (Lin et al., 1995) also involved in regulating u-PAR expression. Nevertheless, taken together, these data suggest that an activated JNK1-dependent signaling module is a critical requirement for the stimulation of u-PAR promoter activity by PMA.
The expression of an activated MEKK1 stimulates u-PAR promoter activity in a JNK1-dependent manner To obtain further evidence for a role of the JNK1 pathway in the regulation of u-PAR expression by PMA we determined whether the expression of a constitutively active MEKK1 was inductive for u-PAR promoter activity. OVCAR-3 cells were transfected with the u-PAR-regulated CAT reporter and an expression construct bearing a constitutively active MEKK1 . The activity of the u-PAR promoter was below the detection limit in cells transfected only with the reporter construct (Figure 6) . However, the expression of the constitutively active MEKK1 caused a dramatic induction of u-PAR promoter activity. This was not a vector eect since the empty construct (CMV Vector) failed to augment u-PAR promoter activity. The co-expression of a twofold molar excess of the mutated JNK1 expression construct inhibited promoter activation by 65% when compared with that achieved with the empty expression construct (SRa Vector). These data are consistent with the notion that u-PAR promoter activity is regulated by a JNK1-dependent signaling pathway. Figure 4 The c-Raf-1-ERK and JNK-dependent signaling cascades are shown. The molecular targets for the dominant negative expression constructs used herein are indicated Figure 5 The expression of either a kinase-defective JNK1 or a dominant negative MEKK1 counters the stimulation of u-PAR promoter activity achieved with PMA. OVCAR-3 cells were transfected with 1 mg of a promoter-less (pSV 0 CAT) or a u-PAR promoter (u-PAR CAT)-regulated CAT reporter and an expression vector (SRa Vector) encoding either a kinase-defective JNK1 (JNK1 mt sRa a) or a dominant negative MEKK1 (MEKKmt SRa b). The amounts of the mutated JNK1-or MEKK1-expressing constructs (or empty vector) are indicated as a molar excess relative to the u-PAR promoter-regulated CAT reporter construct. After 6 h, the cells were washed and treated with (+), or without (7), 100 nM PMA. The cells were cultured for an additional 48 h, lysed and assayed for CAT activity. The percentage of [ 14 C]chloramphenicol converted was determined using a 603 Betascope. The experiments were repeated twice Increased u-PAR expression by PMA and c-Ha-ras is JNK1 dependent
The stimulation of u-PAR promoter activity by PMA is PD 098059-sensitive While our data indicated a role for a JNK1-dependent signaling cascade in stimulation of u-PAR expression by PMA this did not necessarily mean that the regulation of u-PAR expression was mediated exclusively through this cascade. Further, since several studies have suggested that the eect of PMA on AP-1-regulated gene expression is via an ERK-dependent signaling pathway we undertook experiments to determine whether an inhibitor of ERK activation interfered with the stimulation of u-PAR expression by the phorbol ester. PD 098059 speci®cally inhibits MEK1 activation Alessi et al., 1995) and treatment of OVCAR-3 cells with concentrations that prevent ERK activation in cultured cells Alessi et al., 1995) , diminished the PMA-dependent stimulation of u-PAR promoter activity from seven to twofold (Figure 7 ). These data suggest that while the stimulation of u-PAR expression by PMA is JNK1-dependent, it also requires an ERKdependent signaling cascade.
The stimulation of u-PAR promoter activity by the expression of an activated c-Ha-Ras requires an intact JNK1-dependent signaling module
Although the data presented indicate a role for JNK1 in mediating the inductive eects of phorbol ester on u-PAR expression, does this represent a biological means of regulating u-PAR expression? Since, both K-Ras and c-Ha-ras are overexpressed and/or mutationactivated in several malignancies including ovarian cancer and considering that this is predictive of recurrent or persistent disease (Bos, 1989; Chien et al., 1993; van Dam et al., 1994; Palejwala et al., 1996; Scambia et al., 1997) we therefore determined whether the JNK1 signaling module was required for stimulation of the u-PAR promoter by this oncogene. Towards this end, we ®rst transfected OVCAR-3 cells, which contain a wild type c-Ha-Ras, with the u-PAR promoter-driven CAT reporter and varying amounts of an expression construct encoding a mutation-activated c-Ha-Ras (Figure 8) . The expres- Figure 6 The stimulation of u-PAR promoter activity by the expression of a constitutively active MEKK1 can be antagonized by the co-expression of a dominant negative JNK1-bearing plasmid. OVCAR-3 cells were co-transfected with 8 mg of a u-PAR promoter-regulated CAT reporter (u-PAR CAT) and 1 mg of an expression construct (CMV Vector) encoding a constitutively active MEKK1 (MEKKactive) with, or without, the indicated molar excess (relative to the reporter) of a plasmid (SRa Vector) expressing a kinase-defective JNK1 (JNK1 SRa). After 48 h, the cells were lysed and equal amount of protein assayed for CAT activity. The amount of [ Figure 8 The expression of c-Ha-Ras stimulates u-PAR promoter activity in a dose-dependent manner. OVCAR-3 cells were co-transfected with a promoter-less CAT reporter (pSV 0 CAT) or a u-PAR promoter-regulated CAT reporter (u-PAR CAT) with either the indicated amount of an activated c-Ha-Rasexpression plasmid or the molar equivalent (corresponding with 10 mg of c-Ha-Ras-expressing plasmid) of a control plasmid (pSV 2 neo) with the same vector backbone. After 48 h, cell extracts were made and assayed for CAT activity. The percentage of [ 14 C]chloramphenicol converted to acetylated derivatives was determined using a 603 Betascope Increased u-PAR expression by PMA and c-Ha-ras is JNK1 dependentsion construct caused a dose-dependent increase in u-PAR promoter activity. This was unrelated to the vector backbone since the transfection of the cells with an expression construct bearing a control gene (pSV 2 neo) failed to stimulate u-PAR promoter activity. This is the ®rst report showing stimulation of the u-PAR gene by an activated Ras.
The ability of the activated c-Ha-Ras to stimulate u-PAR promoter activity in the presence of expression vectors bearing mutated signaling kinases in the JNK1 signaling cascade was then determined. JNK activity has previously been shown to be regulated by the sequential activation of Rac1, MEKK1, JNKK and JNK Lin et al., 1995; Derijard et al., 1995) . Transfection of OVCAR-3 cells with a 0.16 molar amount of a dominant negative Rac1 expression construct resulted (Figure 9a ) in approximately a 50% reduction (compared with the empty expression construct-SRa Vector) in the stimulation of u-PAR promoter activity by the activated c-Ha-Ras. An equimolar amount of the mutated Rac1 resulted in a further decrease in u-PAR promoter activity (70% reduction in the amount of acetylated chloramphenicol). Parallel experiments with the kinase-de®cient MEKK1 (Figure 9b ) gave similar results with a 0.16 molar amount of the expression construct reducing u-PAR promoter activity by over 90%. Finally, we found that the kinase-inactive JNK1 expression construct countered the stimulation of u-PAR promoter activity by c-Ha-Ras (Figure 9c ) with an equimolar amount of the dominant negative plasmid resulting in over 65% inhibition compared with the empty vector (SRa Vector). Taken together, these results suggest that while c-Ha-ras can activate multiple downstream signaling cascades (Deng and Karin 1995; RodriguezViciana et al., 1994; Russell et al., 1995; Kolch et al., 1991) , u-PAR promoter activity in OVCAR-3 cells is regulated by this oncogene partly through a JNKdependent signaling module.
Discussion
The u-PAR promotes tumor cell invasion and several studies have demonstrated that down-regulation of the expression of this gene reduces the invasive and, in some cases, the metastatic capacity of a diverse set of malignancies (Kook et al., 1994; Xing et al., 1997; Quattrone et al., 1995) . Thus, it is critical to understand how the expression of this receptor is regulated. We present evidence herein that the induction of u-PAR expression by phorbol ester in an ovarian cancer cell line (OVCAR-3) requires JNK1-dependent and JNK1-independent signaling cascades. To the knowledge of the authors, this is the ®rst report to show that the inductive eect of this phorbol ester on the expression of a natural gene (rather than a synthetic promoter) requires a JNK1-dependent signaling module. Equally important, our studies show, for the ®rst time, that the u-PAR promoter is up-regulated by an activated c-Ha-ras and that this requires a JNK1-dependent signaling cascade. Considering the ®ndings by other investigators of the mutationactivation and/or overexpression of c-Ha-Ras/K-Ras in ovarian and other cancers (Bos, 1989; Chien et al., 1993; van Dam et al., 1994; Palejwala et al., 1996; Scambia et al., 1997) , these latter observations may explain, in part, the observation of higher u-PAR levels in malignant ovarian tumors (Casslen et al., 1991) .
While an intact JNK1-dependent signaling module is critical for the induction of u-PAR expression by PMA, we do not feel that the activation of this MAPK is sucient to up-regulate the synthesis of u-PAR. Indeed, there also appears to be an ERK requirement since an inhibitor (PD 098059) of the upstream Figure 9 The Ras-dependent stimulation of u-PAR promoter activity is inhibited by the co-expression of plasmids encoding dominant negative Rac-1, MEKK1 or JNK1. OVCAR-3 cells were co-transfected with 2 mg of a u-PAR promoter-regulated CAT reporter (u-PAR CAT), 5 mg of a vector bearing an activated Ras (c-Ha-Ras) or neo (pSV 2 neo), and a plasmid (SRa Vector) encoding either a dominant negative Rac-1 (Rac-1 mt SRa-a), a mutated MEKK1 (MEKKmt SRa b) or a kinasedefective JNK1 (JNK1 mt SRa-c). The amount of each dominant negative expression construct is in molar equivalents relative to the CAT reporter. The cells were cultured for an additional 48 h, lysed and assayed for CAT activity. The percentage of [ 14 C]chloramphenicol converted was determined using a 603 Betascope. The experiments were repeated twice Increased u-PAR expression by PMA and c-Ha-ras is JNK1 dependentactivator (MEK1) was very eective in blocking the PMA-dependent induction of u-PAR promoter activity. Additionally, PMA caused a rapid increase in ERK1 activity which paralleled the elevation in JNK activity. The involvement of the c-Raf-1-ERK signaling cascade in the modulation of gene expression by this phorbol ester is well established (Jones et al., 1994; Masuelli and Cutler, 1996; Whalen et al., 1997; de Vries-Smits et al., 1992; Bogoyevitch et al., 1995; Cai et al., 1997; Sozeri et al., 1992; Berra et al., 1995) . These observations, combined with our unpublished ®nding that anisomycin, a selective activator of the JNKs (Bogoyevitch et al., 1995; Cano et al., 1994) , does not increase u-PAR display, makes it likely that the propagation of the PMA stimulus to the nuclear transcriptional machinery regulating u-PAR expression is dependent on the cooperation of both JNK1-and ERK-dependent signaling modules. Indeed the cooperation of both of these signaling cascades in the transformation of NIH3T3 cells (Khosravi-far et al., 1995) and in the activation of a PEA3-regulated synthetic promoter (O'Hagan et al., 1996) by Ras has been reported.
However, if mutiple signaling cascades are required for u-PAR expression, two observations merit explanation. First, if the stimulation of u-PAR expression brought about by PMA represents the convergence of multiple signaling modules, how then do we explain the ®nding that the expression of a constitutively active MEKK1, which lies upstream of JNK1, is sucient to up-regulate u-PAR promoter activity? This might be explained by the observations (Lange-Carter et al., 1993) that the high expression of a MEKK1-bearing plasmid may result in the activation of ERKs lying in the parallel c-Raf-1-ERK pathway. Second, we previously reported that in the GEO colon cancer cell line u-PAR promoter activity was stimulated by the expression of a constitutively activated MEK1 construct. Again, this ®nding initially appears divergent with the data generated in the current study where the ability of PMA to induce u-PAR expression requires both ERK-and JNK1-dependent signaling pathways. Subsequent analysis has shown that GEO cells have a substantial basal JNK activity and it could be that this endogenous JNK-dependent signaling pathway acts in concert with an ERK module activated by the exogenous MEK1 expression construct. Alternatively, the regulation of u-PAR expression may dier in the separate cell lines studied.
The convergence point for PMA in the JNK1-signaling module deserves comment. The fact that dominant negative expression vectors to Rac-1 and MEKK1 could counter the stimulation of u-PAR promoter activity by PMA suggests that the phorbol ester is mediating its eect at the proximal, rather than at the distal, end of the signaling module. Interestingly, Blumer et al. (1994) reported that in Saccharomyces cerevisiae the expression of a catalytic domain of MEKK corrected the cell-lysis defect of a pkc1 delta domain in a mutant that lacks a protein kinase C homologue. Thus, this study would suggest that, at least in yeast, MEKK1 functions downstream of the protein kinase C gene product.
How does PMA modulate u-PAR gene expression at the transcriptional level? Our data suggest that this is, in part, via c-Jun transactivating u-PAR gene expression through the AP-1 motif at 7184. Thus, this transcription factor was the main AP-1-binding factor in nuclear extracts from PMA-treated OVCAR-3 cells bound to the u-PAR AP-1 motif at 7184. Additionally, PMA stimulated the transcription from a GAL4-regulated luciferase reporter construct in OV-CAR-3 cells made to co-express a construct bearing a chimeric protein consisting of the transactivation domain of c-Jun fused to the DNA-binding domain of GAL4. Increased transcriptional activity of c-Jun has been ascribed to phosphorylation of residues 63 and 73 in the transactivation domain of this DNAbinding factor and prevailing evidence suggest that this is achieved through the JNKs rather than the ERKs (Hibi et al., 1993; Minden et al., 1994b) . Interestingly, in a previous study, it was reported that PMA stimulates the phosphorylation of these serine residues (Wasylyk et al., 1994; Franklin et al., 1992) . However, in those studies the authors concluded that the phosphorylation of c-Jun was due to ERK1 and ERK2 (Pulverer et al., 1993) . The increased binding of c-Fos to the AP-1 motif in PMA-treated OVCAR-3 cells was also evident. This could represent stimulation of c-Fos expression by way of phosphorylation and activation of Elk-1 or Sap-1a (Whitmarsh et al., 1997; Janknecht and Hunter, 1997) by JNK1. Alternatively, this could be a result of a parallel stimulation of the classical c-Raf-1-ERK pathway by PMA leading to increased c-Fos expression via the phosphorylation of p62 TCF (Gille et al., 1992) . Indeed, our observation that an inhibitor of ERK activation (PD 098059) countered u-PAR promoter stimulation by PMA is consistent with this notion.
While the stimulation of JNK activity is often associated with stress or apoptosis-inducing stimuli such as osmotic stress or g or ultraviolet irradiation (Derijard et al., 1994; Bogoyevitch et al., 1995; Rosette and Karin, 1996; Chen et al., 1996) , emerging studies are suggesting that this MAPK is involved in mediating growth' responses. Recently, Natoli et al. (1997) reported that TNF activation of JNK occurred through a noncytotoxic TRAF2-dependent pathway and concluded that JNK activation was via a pathway independent of apoptosis. In a separate study, Silberman et al. (1997) concluded that in Ras-transformed NIH3T3 cells the JNK pathway acted as a switch between two dierent protease phenotypes with a high JNK activity being associated with urokinase (the receptor was not examined) expression. Finally, the stimulation of atrial natriuretic factor (ANF) by aadrenergic receptor stimulation required a JNKdependent signaling cascade as evidenced by the ability of a dominant negative MEKK expression construct to block expression and by the increased JNK activity evident in mice overexpressing an oncogenic Ras . Thus, our ®nding that up-regulation of u-PAR expression involves a JNK1-dependent signaling cascade is in keeping with the emerging role for this MAPK as a regulator of growth-associated gene expression.
In conclusion, our study shows that the stimulation of u-PAR expression by PMA in an ovarian cancer cell requires a JNK1-dependent signaling cascade which probably acts in concert with a PD 098059-sensitive signaling module. Equally important, the up-regulation of u-PAR promoter activity brought about by a c-HaRas, which has been shown to be mutation-activated, or overexpressed, in a variety of malignancies including ovarian, colon, lung and pancreas cancers (Bos, 1989; Chien et al., 1993; van Dam et al., 1994; Palejwala et al., 1996; Scambia et al., 1997) , is also dependent on a JNK1-dependent signaling cascade. Finally, our study serves to illustrate that the concept of linear signaling modules connecting the cell membrane to the nuclear transcriptional machinery is overly simplistic and probably unre¯ective of the complex regulation of inducible gene expression.
Materials and methods
DNA constructs
The wild type u-PAR promoter-driven CAT reporter consists of 398 base pairs of upstream sequence of the u-PAR gene (relative to the transcription start site) cloned into the XbaI site of the pCAT-Basic vector (Promega, Madison, Wisconsin) (Wang et al., 1995) . The AP-1 mutated (7184) u-PAR promoter-regulated CAT reporter has been described previously (Lengyel et al., 1996) . The dominant negative JNK1 expression construct includes the coding sequence of JNK1 in which threonine 183 and tyrosine 185 are substituted with alanine and phenylalanine respectively (Derijard et al., 1994) . The dominant negative MEKK1 plasmid encodes a MEKK1 cDNA harboring a lysine to methionine substitution at residue 432 and lacking the Nco fragment from the aminoterminus (Minden et al., 1994a) . The constitutively active MEKK1 was as described elsewhere . A 6.6 kb BamHI fragment from the activated c-Ha-ras EJ oncogene from T24 bladder carcinoma cells cloned in a pSV2neo plasmid (Nicholson et al., 1990) was used for ras transfections. The dominant negative Rac-1 expression construct consists of the full coding sequence of Rac-1 in which threonine at codon 17 was replaced with asparagine (Coso et al., 1995) . The PathDetect TM (Stratagene, LaJolla, California) system used was the c-Jun-trans-Reporting System (#219000) and consists of the following components (a) a luciferase reporter plasmid containing 5 tandem repeats of the yeast GAL4 binding site upstream of the luciferase gene, (b) an expression construct encoding either the DNAbinding domain of GAL4 only or the activation domain of cJun fused to the GAL4 DNA-binding domain and (c) a MEKK-expressing plasmid used as a positive control.
JNK activity assays
There were as described elsewhere with modi®cations (Coso et al., 1995; Gum et al., 1997) . Cell extracts (equal protein) were incubated at 48C for 2 h with 1.5 mg of an anti-JNK antibody (Santa Cruz Biotechnology # sc-474) which is crossreactive with human JNK1 and JNK2. Protein A agarose beads were then added to the mixture and incubated for an additional 1.5 h at 48C. The beads were rinsed several times and then incubated in 30 ml of kinase buer (12.5 mM MOPS (pH 7.5), 7.5 mM MgCl 2 , 12.5 mM b-glycerophosphate, 0.5 mM EGTA, 0.5 mM NaF, 0.5 mM sodium vanadate) with 1 mCi [g 32 P]ATP, 2 mg GST-c-Jun protein (c-Jun amino acid residues 1 ± 79 -Santa Cruz Biotechnology #sc-4113) and 20 mM cold ATP at 308C. The reaction was terminated 20 min later with 26 Laemmli's buer, heated to 1008C and the beads removed by centrifugation. The supernatant was electrophoresed in a 12% polyacrylamide gel. The gel was dried and autoradiographed. The amount of JNK activity was quantitated using a Storm 840 Phosphorimagor (Molecular Dynamics, Sunnyvale, California) using ImageQuant software (Molecular Dynamics).
ERK assays
Assays for ERK activity were carried out as described elsewhere (Morino et al., 1995; Lengyel et al., 1997) but with minor modi®cations. Brie¯y, cells were extracted in a 1% Nonidet P-40 buer containing 1 mM sodium vanadate, 10 mM NaF, 10 mM sodium pyrophosphate, 10 nM okadaic acid, 0.5 mM EGTA and 1 mM PMSF. Insoluble material was removed by centrifugation and the cell extracts, containing an equal amount of protein, incubated at 48C for 1 h simultaneously with 0.5 mg of the anti-ERK1/ERK2 antibody (Santa Cruz Biotechnology # 93) and Protein-A agarose beads. The beads were washed with 1% Nonidet P-40 lysis buer, resuspended in 36 sample buer, and the immune complexes electrophoresed in an SDS-polyacrylamide gel containing 0.5 mg/ml myelin basic protein (MBP). SDS was removed from the gel with 20% 2-propanol in 50 mM Tris-HCl (pH 8.0) and then with 50 mM Tris-HCl containing 5 mM 2-mercaptoethanol. The gel was then treated with two changes of 6 M guanidine HCl and then with 50 mM Tris-HCl (pH 8.0) containing 0.04% Tween 40 and 5 mM 2-mercaptoethanol. Subsequently, the gel was preincubated at 258C for 1 h with a 40 mM HEPES (pH 8.0) solution containing 2 mM dithiothreitol, 0.1 mM EGTA and 5 mM MgCl 2 . Phosphorylation of MBP was carried out by incubating the gel at 258C for 1 h in the same buer supplemented with 40 mM ATP, and 25 mCi of [g 32 P]ATP. After incubation, the gel was washed thoroughly in a solution containing 5% TCA and 1% sodium pyrophosphate then dried and autoradiographed. The amount of myelin basic protein phosphorylated was quanti®ed using a Storm 840 Phosphorimagor and ImageQuant software.
Quantitation of u-PAR by Immunoprecipitation/Western blotting
Cells were extracted into a buer (10 mM Tris pH 7.4, 0.15 M NaCl, 1% Triton X-100, 0.5% NP-40, 20 mg/ml aprotinin, 1 mM PMSF, 1 mM EGTA, 1 mM EDTA) for 10 min at 48C. Insoluble material was removed by centrifugation and 750 mg protein of cell extract immunoprecipitated at 48C for 16 h with 0.25 mg of a polyclonal anti-u-PAR antibody and protein A agarose beads. The polyclonal antibody was raised in rabbits against amino acids 1 ± 281 of the human u-PAR and puri®ed on a Sepharose-immobilized u-PAR column. The beads were subsequently recovered by centrifugation. The immunoprecipitated material was denatured in an SDS solution containing 160 mM dithiothreitol at 1008C and resolved in a 10.5% polyacrylamide gel. The proteins were transferred to a nitrocellulose ®lter and, after blocking with 3% BSA, the blot probed with 5 mg/ml of an anti-u-PAR monoclonal antibody (#3931 American Diagnostica, Greenwich, CT) and an HRP-conjugated goat anti-mouse IgG. Bands were visualized by enhanced chemiluminescence (Amersham, Arlington Heights, Illinois).
CAT assays
OVCAR-3 cells were transfected at approximately 60% con¯uency using poly-L-ornithine as described previously (Nead and McCance, 1995) . Essentially, the cells were incubated with DNA and 31 mg poly-L-ornithine (Sigma Chemicals, St Louis, MO). After 6 h, the cells were replenished with fresh culture medium supplemented with, or without, phorbol 12-myristate 13-acetate (PMA). After 48 h, all cells were harvested and lysed by repeated freezethaw cycles in a buer containing 0.25 M Tris-Cl pH 7.8. Transfection eciencies were determined by including an RSV-luciferase expression construct in the DNA mixture and assaying for luciferase activity. CAT activity was Increased u-PAR expression by PMA and c-Ha-ras is JNK1 dependent R Gum et al measured by incubating cell lysates (normalized for transfection eciency) at 378C for 6 h with 4 mM [ 14 C]chloramphenicol and 1 mg/ml acetyl Coenzyme A. After 3 h, the acetyl Coenzyme A was replenished. The mixture was extracted with ethyl acetate and acetylated products subjected to thin layer chromatography using chloroform: methanol (95 : 5) as a mobile phase. The amount of acetylated [ 14 C]-chloramphenicol was determined using a 603 Betascope.
Detection of c-Jun trans-activating activity using the PathDetect TM System
These were performed as described by the manufacturer (Stratagene, La Jolla, California). Transient transfections were as described for the CAT assays with the exception that the cells were lysed with Reporter lysis 56 buer (Promega, Madison, Wisconsin). Luciferase activities were determined using a luminometer (Analytical Luminescence Laboratory, Ann Arbor, Michigan).
Mobility shift assays
Nuclear extracts were prepared as described elsewhere (Dignam et al., 1983) and 6 mg incubated at 48C for 10 min in a buer (25 mM HEPES buer pH 7.9, 0.5 mM EDTA, 0.5 mM DTT, 0.05 M NaCl and 2.5% glycerol) with 1 mg of poly dI/dC and 5 fmoles (2610 4 c.p.m.) of a Klenow endlabeled a 32 P-ATP oligonucleotide (7199 GTGATCA-CAACTCCATGAGTCAGGGCCGAT 7170) in the absence, or presence, of a 100-fold excess of the wild type competitor sequence. After this time, 2 mg of the indicated antibody was added and the incubation continued for 45 min. The reaction mixture was electrophoresed in a 5% polyacrylamide gel, containing 5% glycerol using 0.56TBE (89 mM Tris, 89 mM boric acid and 1 mM EDTA) running buer. The gel was rinsed with water, dried and exposed to X-ray ®lm overnight.
